Ignite Creation Date:
2025-12-25 @ 3:18 AM
Ignite Modification Date:
2026-02-22 @ 2:13 AM
Study NCT ID:
NCT02202005
Status:
COMPLETED
Last Update Posted:
2015-08-25
First Post:
2014-07-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D019829', 'term': 'Nevirapine'}], 'ancestors': [{'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 46}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-08', 'completionDateStruct': {'date': '2015-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-08-21', 'studyFirstSubmitDate': '2014-07-24', 'studyFirstSubmitQcDate': '2014-07-24', 'lastUpdatePostDateStruct': {'date': '2015-08-25', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-07-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Plasma concentrations by AUC0 τ,ss (area under the concentration time curve)', 'timeFrame': 'Days 14, 28, 42, 56'}, {'measure': 'Cτ,ss (defined as concentration at the end of dosing interval)', 'timeFrame': 'Days 14, 28, 42, 56'}, {'measure': 'Cmax,ss (maximum observed plasma concentration)', 'timeFrame': 'Days 14, 28, 42, 56'}], 'secondaryOutcomes': [{'measure': 'Percentage of fluctuation over one dosing interval at steady state (Fl(%)', 'timeFrame': 'Days 14, 28, 42, 56'}, {'measure': 'Tmax,ss (the time to maximum plasma concentration at steady state)', 'timeFrame': 'Days 14, 28, 42, 56'}, {'measure': 'Cmin,ss (minimum plasma concentration at steady state)', 'timeFrame': 'Days 14, 28, 42, 56'}, {'measure': 'Average plasma drug concentration', 'timeFrame': 'Days 14, 28, 42, 56'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Bioequivalence'], 'conditions': ['HIV-1']}, 'descriptionModule': {'briefSummary': 'The objective of this steady state pivotal study is to compare the rate and extent of absorption and to evaluate Bioequivalence of test drug compared to the approved reference product in HIV infected individuals'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Signed and dated written informed consent prior to admission to the study\n2. HIV1 infected males or females of 18 to 65 years, nonsmoker (use of cannabis may be accepted)\n3. Body weight ≥ 50.0 kg and BMI ≥ 18.0 and ≤ 32.0 kg/m2\n4. Absence of clinically significant history of neurological, endocrinal, cardiovascular, pulmonary, haematological, psychiatric, gastrointestinal, renal, hepatic, obstructive disorders, cholestasis, and metabolic disease\n5. Treatment with a stable nevirapine based combination regimen for at least the preceding 12 weeks (or 6 weeks if switched from an antiretroviral regimen containing two nucleoside analogues and efavirenz)\n6. Background HIV therapy with a stable antiretroviral regimen that is recommended in combination with nevirapine according to British HIV Association clinical guidelines:\n\n 1. Abacavir and lamivudine {ABC/3TC} as fixed dose combination Kivexa\n 2. Tenofovir and emtricitabine {TDF/FTC} Truvada\n 3. Zidovudine and lamivudine {AZT/3TC} - Combivir, OR\n 4. Tenofovir and lamivudine as separately prescribed components and kept constant (in combination and dosage) throughout the whole course of the study\n7. An HIV viral load \\< 50 copies/mL in preceding 3 months and at screening\n8. A CD4+ Tcell count \\> 50 cell/mm3\n9. Acceptable screening laboratory values that indicate adequate baseline organ function\n10. Willingness to abstain from ingesting medications that are listed as contraindicated for nevirapine during the whole course of the study\n11. Capable of completing patient diaries\n12. Capable and willing to come back for PK assessments and follow up\n13. Willingness to refrain from excessive physical activity during the trial\n14. Willingness of male study participants to not father a child during and throughout the study. To prevent a pregnancy of the female partner, both the male study participant and the female partner need to take appropriate contraceptives to prevent pregnancy during the study.\n\nExclusion Criteria:\n\n1. Infection with HIV2 or HIV1 group O.\n2. Current treatment with an HIV protease inhibitor\n3. Participation in any other study within 30 days of Day 1, or intention to participate in another study during participation in this study.\n4. Male and female patients who are not willing to use male or female condoms to prevent HIV transmission\n5. Female patients of childbearing potential who:\n\n 1. Have a positive serum pregnancy test at screening.\n 2. Are breast feeding.\n 3. Are planning to become pregnant\n 4. Are not willing to take appropriate measures to prevent pregnancy during the study\n6. Females who do not use an acceptable contraceptive regimen or confirm total abstinence will be allowed to participate in this study only if they are not considered to be of childbearing potential\n7. Laboratory parameters \\> DAIDS grade 2 Coagulation\n8. Laboratory parameters \\> DAIDS grade 2 Total triglycerides\n9. Hypersensitivity to the active substance or any ingredients of the test or reference investigational products or chemically related compounds.\n10. Contraindication to Nevirapine\n11. Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion\n12. Use of concomitant medication (other than the stable background antiretroviral HIV therapy) that may interfere with the pharmacokinetics of nevirapine and/or the background antiretroviral HIV therapy)\n13. Intake of products containing St. John's Wort from 14 days before treatment with study medication (Day 1) and not willing to abstain from it throughout the study until after the last study visit"}, 'identificationModule': {'nctId': 'NCT02202005', 'briefTitle': 'Multiple Dose BE Study With Nevirapine 400mg PR Tablets', 'organization': {'class': 'INDUSTRY', 'fullName': 'Teva Branded Pharmaceutical Products R&D, Inc.'}, 'officialTitle': "A Multiple Dose, Open Label, Pivotal, 4 Period, 2 Treatment, Sequence Full Replicative Crossover Study to Assess the Bioequivalence (BE) of TEVA's Generic Once Daily Nevirapine 400 mg Prolonged Release (PR) Formulation Compared With the Approved Reference Product Viramune® 400 mg Prolonged Release Tablets Under Fasted Conditions in HIV1 Infected Patients", 'orgStudyIdInfo': {'id': 'NEVIR5U14EU'}, 'secondaryIdInfos': [{'id': '2014-002247-18', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Nevirapine', 'interventionNames': ['Drug: Nevirapine', 'Drug: Viramune®']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Viramune®', 'interventionNames': ['Drug: Nevirapine', 'Drug: Viramune®']}], 'interventions': [{'name': 'Nevirapine', 'type': 'DRUG', 'description': 'Nevirapine 400mg PR tablet', 'armGroupLabels': ['Nevirapine', 'Viramune®']}, {'name': 'Viramune®', 'type': 'DRUG', 'description': 'Viramune® 400 mg Retardtabletten', 'armGroupLabels': ['Nevirapine', 'Viramune®']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'SW10 9TH', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Chelsea and Westminster NHS Foundation Trust', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'Teva Medical Expert, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Chelsea and Westminster NHS Foundation Trust'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ratiopharm GmbH', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}